top of page
Pipeline
Designation
Pre-Clinical Trials
Phase 3
Alzheimer's
Cancer
Development
Phase 2
Phase 1
KCNT1
Alzheimer's
mRNA combined with lipid nanoparticle technology allows for the insertion of any protein back into individuals missing particular important proteins. In the case of Alzheimer's, as your body ages you cease to produce proteins which refold misfolded proteins. These misfolded proteins, if left unchecked, will form the toxic protein aggregates that cause Alzheimer's related deaths. Our patented technology allows us to reinsert these lost proteins back into individuals afflicted by Alzheimers.

bottom of page